disease-modifying antirheumatic drugs

dis·ease-mod·i·fy·ing an·ti·rheu·ma·tic drugs

(DMARD) (di-zēz'mod'i-fī-ing an'tē-rū-mat'ik drŭgz)
Agents that apparently alter the course and progression of rheumatoid arthritis, as opposed to more rapidly acting substances that suppress inflammation and decrease pain, but do not prevent cartilage or bone erosion or progressive disability.

disease-modifying antirheumatic drugs

; DMARDs group of cytokine-inhibiting agents, used singly or in combination, to minimize and/or control inflammation, joint swelling and tissue destruction characteristic of rheumatoid disease, reducing incidence of irreversible joint damage; e.g. penicillamine, gold salts, antimalarials (chloroquine and hydroxychloroquine), drugs affecting the immune response (azathioprine, methotrexate and enteracept), sulfasalazine and corticosteroids

dis·ease-mod·i·fy·ing an·ti·rheu·ma·tic drugs

(DMARD) (di-zēz'mod'i-fī-ing an'tē-rū-mat'ik drŭgz)
Agents that alter the course and progression of rheumatoid arthritis.
References in periodicals archive ?
Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs (Presenting Author: Emery, P.
As a result, clinicians are initiating and emphasizing treatment with traditional disease-modifying antirheumatic drugs (DMARDs) and biologics earlier in the treatment paradigm.
Case 2- A 62-year-old female with RA (Steinbrocker classification: functional class III, stage of disease progression 4) since 1989 was treated with non-biological disease-modifying antirheumatic drugs.
Women with autoimmune diseases who take corticosteroids and disease-modifying antirheumatic drugs later in pregnancy have an increased risk of preterm birth, but this association is largely explained by confounding with sociodemographic and clinical factors and disease severity, a study showed.
XELJANZ may be used as a single agent or in combination with MTX or other non-biologic disease-modifying antirheumatic drugs (DMARDs).
In terms of PsA treatment approaches, an evidence review that he and his associates in GRAPPA published in 2009 found that biologies (anti-tumor necrosis factor inhibitors) as a group were effective in all five domains of the disease: peripheral arthritis, skin and nail disease, axial disease, dactylitis, and enthesitis, while the oral disease-modifying antirheumatic drugs (DMARDs) were effective for peripheral arthritis and skin and nail disease.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.
Washington, June 22 (ANI): Researchers at Brigham and Women's Hospital have found that two disease-modifying antirheumatic drugs (DMARDs) are associated with a reduced risk for the development of diabetes in psoriasis and rheumatoid arthritis patients.
The drug will now be an option when the disease has responded inadequately to disease-modifying antirheumatic drugs (DMARDs) and is already used in 1,200 patients at later stages of the disease.
Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate.
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Although many disease-modifying antirheumatic drugs (DMARDs) and biologic agents are used in the treatment of this disease, new pharmaceutical drugs are required to achieve better efficacy.